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Abstract
Background: Clinically annotated specimens from cancer clinical trial participants offer an opportunity for discovery and 
validation of pharmacogenomic findings. The purpose of this observational study is to better understand patient/institution 
factors that may contribute to participation in the pharmacogenomic component of prospective cancer clinical trials.
Methods: Patient demographic information (age, sex, self-reported race) and institutional characteristics (CALGB/
CTSU site, “diversity,” and accrual) were evaluated for 8456 patients enrolled in seven CALGB phase III studies with a 
pharmacogenomic component. All statistical tests were two-sided.
Results: The majority of patients (81%) consented to participate in the pharmacogenomic component. However, in a 
multivariable analysis, site (CALGB vs CTSU) and “institutional diversity” (percent minority cancer patients on national 
trials) were statistically significantly associated with participation. For both whites and nonwhites, patients from CALGB 
sites were more likely to participate compared with patients from CTSU sites (whites: odds ratio [OR] = 2.26, 95% confidence 
interval [CI] = 1.68 to 3.04, P < .001; nonwhites: OR = 1.79, 95% CI = 1.52 to 2.11, P < .001). However, as “institutional diversity” 
increased, the likelihood of participation in the pharmacogenomics component decreased for both white (OR = 0.94, 95% 
CI = 0.91 to 0.97, P < .001) and nonwhite patients (OR = 0.90, 95% CI = 0.81 to 1.00, P = .05).
Conclusions: Most clinical trial cancer patients across geographical, racial, and practice settings are willing to participate 
in pharmacogenomic studies. However, to promote equitable benefit to the larger cancer community, optimization 
of both patient and institutional participation are needed. Institutional factors may be even more compelling than 
patient demographics. Prospective studies are needed to identify and address barriers/incentives to participation in 
pharmacogenomic research at the patient, clinician, and institutional levels.
Pharmacogenomics is the study of heritable and somatic 
genomic variation associated with drug response, including the 
prediction of toxicity and effectiveness (1–3). The field holds the 
promise of providing objective ways to individualize therapy, 
especially in the treatment of cancer patients (4,5). An efficient 
strategy to conduct these studies is to incorporate pharmacog-
enomics into prospective cancer clinical trials (6), especially 
large phase III studies (7). To study heritable variations in the 











clinical trial setting, germline DNA is extracted from blood sam-
ples of study patients who provide consent to participate in this 
component of the clinical trial.
The current observational study evaluates the participa-
tion of more than 8000 cancer patients in the inherited phar-
macogenomics portion of seven different clinical trials from 
the Cancer and Leukemia Group B (CALGB) (now part of the 
Alliance for Clinical Trials in Oncology). Although many stud-
ies have evaluated participation in adult cancer clinical trials 
(6, 8–14), unique to this study is the evaluation of participation 
in the optional pharmacogenomics component among a group 
of cancer patients who have already agreed to participate in 
the clinical drug trial. The CALGB was among the first National 
Cancer Institute (NCI)–cooperative oncology groups to provide 
the opportunity for cancer patients to participate in optional 
pharmacogenomics studies, where germline DNA was collected 
from consenting patients to assess the relationship of heritable 
variations with clinical outcome (15).
In 2002, when these pharmacogenomic companion stud-
ies started, it was routine to collect tumor tissue for correlative 
science studies. However, it was not routine to collect germline 
DNA for genetic research, whether the intent was to evaluate 
inherited susceptibility to cancer development or to evaluate 
inherited pharmacogenomic variations to predict response 
to therapy. The pharmacogenomics studies reported in this 
manuscript represent one of the first times that an NCI-funded 
cooperative group was asking patients to contribute germline 
DNA to gain a better understanding of predicting response to 
anticancer treatments. None of these pharmacogenomic stud-
ies were utilizing pharmacogenomic results to guide therapy; 
all were collecting germline DNA for future pharmacogenomic 
research. Considering the general concerns reported in the liter-
ature at the time regarding fear of genetic research and misuse 
of genetic research information (16–23), our hypothesis was that 
participation in pharmacogenomic studies may be low because 
of the genetic (inherited) nature of these DNA studies. Although 
studies in the literature have reported on potential barriers to 
participation in clinical cancer trials and correlative tumor tis-
sue studies (9,24–27), none, to our knowledge, have evaluated 
participation in a study of the genetics of drug response in can-
cer patients already participating in clinical trial research. In 
addition, to our knowledge, there have been no other reports 
evaluating participation in cancer pharmacogenomic studies in 
the context of multicenter clinical trials.
The primary aim of the current observational study was to 
evaluate the frequency with which cancer patients who had 
agreed to participate in a clinical cancer drug trial were partici-
pating in the optional germline pharmacogenomics component. 
Utilizing data already captured in the CALGB/Alliance database 
at the time of patient registration, we sought to identify patient 
and institutional factors that may contribute to participation in 




This study includes the initial seven optional pharmacogenomic 
studies embedded in CALGB phase III trials. The studies accrued 
patients from May 2002 to May 2013; all studies are now closed 
to accrual. All clinical trial studies, including the pharmacog-
enomic portion, were also available for registration by non-
CALGB sites through the National Institutes of Health (NIH) 
Clinical Trials Support Unit (a service of the National Cancer 
Institute designed to facilitate access to NCI-funded clinical 
trials for qualified clinical sites and to support the manage-
ment and conduct of those clinical trials). The trials included 
six different disease types: non-Hodgkin’s lymphoma (NHL) and 
breast, gastric, colorectal, pancreatic, and prostate cancer. The 
pharmacogenomic component was open to patient registration 
at the same time as the clinical trial in six of the seven trials. 
Institutional review board (IRB) approval was obtained at each 
site prior to patient registration to the clinical trial or optional 
companion studies.
Patient Selection
All patients (from CALGB and CTSU sites) registered to the seven 
treatment protocols were included in the analysis. Patients reg-
istered to CALGB 40101 before November 1, 2003 were excluded 
from the analysis because prior to this date the pharmacog-
enomic portion of the clinical trial had not yet been open to 
accrual.
Data Collection
Patient registration and data collection for the treatment trials 
and optional pharmacogenomic components were handled by 
the Alliance Statistics and Data Center using a secure server 
and database. Patients provided informed consent for treatment 
and optional companion studies; consent to each component of 
the trial was confirmed by each institution during the patient 
registration process. For patient characteristics, we utilized rel-
evant demographic and clinical information collected at the 
time of patient registration to the clinical trial, including age, 
sex, self-reported race, and cancer diagnosis. Institutional char-
acteristics were limited to the information retrievable from the 
CALGB/Alliance database and included the site through which 
the patient was registered to the clinical trial (CALGB or CTSU), 
the institutional accrual patterns to the clinical trial, and, sepa-
rately, to the pharmacogenomic component. Patient participa-
tion in the optional pharmacogenomics portion of the study 
was confirmed by verification of consent in the CALGB database. 
Because patient consent was required for the optional biospeci-
men studies (eg, blood samples for pharmacogenomics, tumor 
tissue samples for correlative science) and any other companion 
studies (eg, health outcomes, quality of life, imaging), participa-
tion in the pharmacogenomics component of the study could be 
compared with participation in other companion studies.
Informed Consent Documents
All consent questions related to the optional pharmacogenomic 
and other laboratory tissue biomarker studies were included 
in a separate section of the clinical study consent document, 
termed “optional studies.” This section was always found at 
the end of the main consent document. All consents for these 
optional studies included checkboxes to allow patients to opt 
in or opt out of each correlative study (pharmacogenomic and 
tissue), including providing their specimens for future use (eg, 
you can use my sample for future genetic research, future can-
cer research, future noncancer research), with exact language 
varying slightly from study to study. All consent documents 
indicated that there was some risk involved in genetic research 
and described that samples and data were to be coded to pro-
tect individual privacy and confidentiality of information. Local 











IRBs at both CALGB and CTSU institutions may choose to add 
additional language about risk to these consents, based on local 
policy; however, those language changes must be in compliance 
with the standard template language required by NCI for cooper-
ative group study consents, including language for optional cor-
relative science studies. No changes can be made to the consent 
questions. Overall, across the seven studies, we did not observe 
any feature or combination of features of the consent document 
associated with participation to the pharmacogenomics study.
Statistical Methods
Descriptive analysis was conducted using data collected in the 
CALGB database. Self-reported race categories were dichoto-
mized and collapsed into white (Caucasian) vs nonwhite 
(African American, Asian, and other (Native American, Pacific 
Islanders, Hawaiian, mixed or multiple races). Only patients 
with known race were included in the analyses. Only 2.5% of 
patients had unknown race.
To look at rate of institutional accrual to the pharmacog-
enomic component of the trial, we evaluated the number of 
patients accrued to the pharmacogenomic study at the institu-
tion per year during the time the institution was actively accru-
ing patients to the study. A Wilcoxon rank-sum test was used to 
compare the distribution of number of patients accrued to either 
the pharmacogenomic study or the specific clinical trial per 
institution between CALGB and CTSU institutions. Chi-squared 
tests were used to compare percentages among groups (eg, phar-
macogenomic participation between individual clinical trials).
We modeled the probability of consent to pharmacogenom-
ics as a function of self-reported race (nonwhite vs white), site 
(CALGB vs CTSU), age (with odds ratios reported for 10-year 
increments), sex (male vs female), and rate of institutional 
accrual to the pharmacogenomic study using a generalized esti-
mating equation (GEE) model with a logistic link (28). The GEE 
models perform logistic regression while accounting for the 
variability of participation or “clustering” among the separate 
clinical trials. This “cluster variable” accounts for the fact that 
patients are clustered within individual clinical trials. The inter-
actions were considered within the context of the multivariable 
GEE model. The inference and estimation of the terms in the 
log-additive GEE models were carried out under an asymptotic 
framework, assuming that the marginal likelihood ratio statistic 
was asymptotically chi-square (29) with appropriate degrees of 
freedom, using SAS PROC GENMOD (version 9.2).
To further understand the statistical interaction between 
patient self-reported race (white vs nonwhite) and site (registra-
tion to the clinical trial by a CALGB institution vs the CTSU mech-
anism) with participation in the pharmacogenomic component 
of the trial, we conducted an exploratory analysis including an 
estimate of “institutional diversity.” To approximate racial diver-
sity at institutions in our study we calculated a proxy, or diver-
sity variable (minority participation fraction [MPF]), based on the 
percentage of nonwhite cancer patients that an institution reg-
istered to any national cooperative group trial (nonwhite cancer 
patients/total cancer patients [white + nonwhite] registered to 
a CTSU trial by that institution). This information was obtained 
from the NCI Regulatory Support System (RSS) database, a reg-
istry that records and archives information from all institutions 
that register a cancer patient through the CTSU mechanism, 
and includes a site identification code and patient race. The 
RSS database was used because of an insufficient number of 
patients per institution to make this estimate using the CALGB 
database when restricted to the 812 institutions participating in 
the phase III CALGB studies included in our study. Assignment 
of the MPF from the RSS database was limited to those institu-
tions that registered 10 or more patients to any of the clinical 
trials in our study. Using the institutional identification code 
and applying the above criteria, 652 of the 812 (80%) institutions 
in our current study were assigned a MPF. The MPF (with odds 
ratio reported for 10% increments) was used in the final multi-
variable model. The relationship between MPF and participation 
was illustrated graphically using box plots where the MPF was 
categorized by 10 levels: 0% (no diversity), 1% to 9%; 10% to 19%, 
20% to 29% and so on, up to 89% (the highest level of diversity 
[MPF] estimated).
All statistical tests were two-sided, and a P value of less than 
.05 was considered statistically significant.
Results
Treatment Trial Characteristics and Patient 
Demographics
A total of 8456 patients were analyzed. Table  1 summarizes 
the patient demographic and treatment trial characteristics. 
Registration to each clinical trial ranged from 238 to 3314 
patients. Self-reported race demonstrated that the majority 
of patients were Caucasian (83.0%, 7019), followed by African 
American (11.1%, 939), Asian (2.5%, 211)  and other (1.0%, 83, 
either Native Hawaiian or Pacific Islander, American Indian 
or Alaska Native, mixed or multiple race). Race was unknown 
for 204 patients (2.4%). Females constituted 59.3% of the 
total patient population, and median age for all patients was 
58.3 years (55 years for females vs 63 years for males, P < .001, 
Wilcoxon rank-sum test).
Patients could be registered to the clinical trial (and pharma-
cogenomic component) as a CALGB site or as a CTSU site (Table 1). 
Different patterns of accrual to the clinical trials were observed 
based on site (CTSU vs CALGB). Of the 8456 patients registered to 
the seven trials, 57.3% were registered through the CTSU mecha-
nism (CTSU sites) and 42.7% through CALGB (CALGB sites). Of the 
812 institutions participating in these trials, the majority (72.8%) 
registered patients through the CTSU. Compared with CTSU 
sites, CALGB institutions had a higher median accrual per insti-
tution to any individual clinical trial (8 vs 4 patients per study, P < 
.001, Wilcoxon rank-sum test), and CALGB sites were more likely 
than CTSU sites to participate in multiple clinical trials (of the 7 
trials included) (P < .001, Chi-squared test).
Patient Consent to the Pharmacogenomic Study
Of the 8456 patients studied, 81.4% (6882) consented to partici-
pate in the pharmacogenomic component of the clinical trial 
(Table  1). Participation ranged from 76.2% (Trial 80101, gastric 
cancer) to 92.0% (Trial 80203, metastatic colorectal cancer) and 
was statistically different between clinical trials (P < .001, Chi-
squared test).
Patient Consent to Pharmacogenomics Compared 
With Other Companion Studies
We compared patient participation (patient consent) to the 
pharmacogenomic component compared with the tumor tissue 
component in those trials providing both types of optional cor-
relative science studies. Table 2 only looks at the clinical trials 
that had both a tumor tissue correlative science component and 











a pharmacogenomics component. The table looks at four cat-
egories of participation in these optional biospecimen studies: 
1) patients who did not consent to contribute any biospecimen—
ie, patients did not consent to participate in the pharmacog-
enomic component and they did not consent to the tumor tissue 
correlative component; 2) patients provided consent only to the 
pharmacogenomic component (and not the tumor tissue com-
ponent); 3) patients provided consent only to the tumor tissue 
component (and not the pharmacogenomic component); and 
4) patients provided consent to participate in both the pharma-
cogenomic and the tumor tissue components. Across all trials, 
it was more likely that a patient would participate in both the 
pharmacogenomic and tissue studies (n = 5200, range = 74.9%-
89.5%) than either one alone. Some patients did not participate 
in either type of biospecimen study (n = 788, varying from 4.2%-
21.8% nonparticipation depending on the trial).
We also evaluated patient participation to the pharmaco-
genomic or tissue studies relative to other available optional 
companions (eg, quality of life, imaging). We observed no evi-
dence to indicate that patients were agreeing to participate in 
other companions and not in the pharmacogenomic study. In 
most trials, patients were participating in the pharmacogenomic 
study and at least one other companion (see Supplementary 
Table 1, available online).
Univariate Analysis
Combining all trials, univariate logistic regression analyses 
demonstrated no statistical differences in participation in the 
pharmacogenomic study by patient age or sex. However, insti-
tutional site (CALGB vs CTSU) and self-reported patient race 
were associated with pharmacogenomic participation (Table 3). 
Table 2. Consent to contribute blood for pharmacogenomics compared with tumor tissue for biomarker studies*
Clinical trial #
Did not consent  
to biospecimen  
No. (%)




Consent to tissue 
only  
No. (%)
Consent to both 
pharmacogenomics 
and tissue  
No. (%)
40101 260 (7.8) 241 (7.3) 286 (8.6) 2527 (76.3)
50303 29 (6.9) 11 (2.4) 10 (2.6) 373 (88.2)
80101 119 (21.8) 7 (1.3) 11 (2.0) 409 (74.9)
80203 10 (4.2) 6 (2.5) 9 (3.8) 213 (89.5)
80405 370 (16.2) 78 (3.4) 157 (6.9) 1678 (73.5)
* Clinical trials that did not collect blood for pharmacogenomics as well as tumor tissue for correlative science are excluded from the table (eg, 90401, 80303).
Table 1. Characteristics of Patients By Clinical Trial























Characteristic No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Sample size 3314 (39.2) 423 (5.0) 546 (6.5) 238 (2.8) 2283 (27.0) 602 (7.1) 1050 (12.4) 8456
Trial status Closed Open Closed Closed Closed Closed Closed ---
Race
 Caucasian 2759 (83.3) 339 (80.1) 403 (73.8) 207 (87.0) 1859 (81.4) 529 (87.9) 923 (87.9) 7019 (83.0)
 African American 362 (10.9) 47 (11.1) 71 (13.0) 27 (11.3) 273 (12.0) 49 (8.1) 110 (10.5) 939 (11.1)
 Asian 62 (1.9) 14 (3.3) 45 (8.2) 1 (0.4) 72 (3.2) 10 (1.7) 7 (0.7) 211 (2.5)
 Other 36 (1.1) 7 (1.7) 4 (0.7) 1 (0.4) 25 (1.1) 5 (0.8) 5 (0.5) 83 (1.0)
 Unknown 95 (2.9) 16 (3.8) 23 (4.2) 2 (0.8) 54 (2.4) 9 (1.5) 5 (0.5) 204 (2.4)
Minority†
 White 2759 (85.7) 339 (83.3) 403 (77.1) 207 (87.7) 1859 (83.4) 529 (89.2) 923 (88.3) 7019 (85.1)
 Nonwhite 460 (14.3) 68 (16.7) 120 (22.9) 29 (12.3) 370 (16.6) 64 (10.8) 122 (11.7) 1233 (14.9)
Sex
 Male NA 226 (53.4) 371 (67.9) 140 (58.8) 1324 (58.0) 329 (54.7) 1050 (100.0) 3440 (40.7)
 Female 3314 (100.0) 197 (46.6) 175 (32.1) 98 (41.2) 959 (42.0) 273 (45.3) NA 5016 (59.3)
Age, y
 Median 53 57.5 58.7 61.3 59.1 64.2 69 58.3
 Range 22.5 – 84.7 18.8 – 86.6 23.2 – 83.1 22 – 84.4 20.8 – 89.5 26.3 – 88.6 41.7 – 93.5 18.8–93.5
Institution
 CTSU 1755 (53.0) 186 (44.0) 384 (70.3) 123 (51.7) 1553 (68.0) 282 (46.8) 564 (53.7) 4847 (57.3)
 CALGB 1559 (47.0) 237 (56.0) 162 (29.7) 115 (48.3) 730 (32.0) 320 (53.0) 486 (46.3) 3609 (42.7)
Consent to  
pharmacogenomics
2768 (83.5) 384 (90.8) 416 (76.2) 219 (92.0) 1756 (76.9) 475 (78.9) 864 (82.3) 6882 (81.4)
* Trial 40101: patients registered before November 1, 2003 are not included in the statistical analysis, as the pharmacogenomics study was not open at that 
time.
† Eight thousand two hundred fifty-two patients with known racial status: white = Caucasian: nonwhite = African American, Asian, and other (Pacific Islander, 
Hawaiian, multirace).











Patients from CALGB sites were more likely to participate com-
pared with patients from CTSU sites (odds ratio [OR]  =  2.08, 
95% confidence interval [CI] = 1.64 to 2.63, P < .001). Nonwhite 
patients were statistically significantly less likely to participate 
compared with whites (OR = 0.50, 95% CI = 0.43 to 0.57, P < .001). 
Overall, 71.4% (880/1233) of nonwhites (African American, Asian, 
other) consented to the pharmacogenomic component, com-
pared with 83.4% (5853/7019) of whites (Caucasian). Participation 
was statistically significantly lower among nonwhites com-
pared with whites within both CALGB and CTSU sites (CALGB: 
OR = 0.43, 95% CI = 0.39 to 0.48, P < .001; CTSU: OR = 0.51, 95% 
CI = 0.43 to 0.61, P < .001) (Table 3).
Evaluating trials separately, Figure 1 illustrates that for each 
individual clinical trial, participation by nonwhite patients was 
consistently lower compared with white patients. Figure 2 illus-
trates that for nearly all individual trials, patient participation 
was higher from CALGB sites compared with CTSU sites.
Institutional Diversity
To further understand the interaction between site and race, 
we conducted an exploratory analysis that included a proxy for 
institutional racial diversity. This proxy was termed minority 
participation fraction (MPF) and reflected the percent minor-
ity cancer patients registered by an institution to any national 
cooperative cancer trial. When this proxy, MPF, was included in 
the multivariable regression analysis, we observed no evidence 
for an interaction with any of the covariates, indicating that the 
MPF diversity measure was an independent variable. The mul-
tivariable model presented in Table  4 is stratified by white vs 
nonwhite patient participation and includes the institutional 
MPF diversity variable. For whites and nonwhites (self-reported 
race), patients from CALGB sites were more likely to participate 
compared with patients from CTSU sites (whites: OR = 2.26, 95% 
CI = 1.68 to 3.04, P < .001; nonwhites: OR = 1.79, 95% CI = 1.52 to 
2.11, P < .001). However, as the MPF diversity variable increased 
(measured in 10% increments), the likelihood of participation in 
the pharmacogenomics component decreased for both white 
(OR = 0.94, 95% CI = 0.91 to 0.97, P < .001) and nonwhite patients 
(OR  =  0.90, 95% CI  =  0.81 to 1.00, P  =  .05) (see Supplementary 
Tables 2 and 3, available online, for additional analyses by site, 
by individual trial).
Figure  3 graphically illustrates the overall relationship 
between MPF and participation in the pharmacogenomic com-
ponent. MPF was categorized into 10 levels (0%; 1%-9%; 10%-19%, 
Table 3. Factors associated with pharmacogenomic study participa-
tion: univariate model*
Variable OR (95% CI) P
Site: CALGB vs CTSU 2.08 (1.64 to 2.63) <.001
Self-reported race†: nonwhite vs white 0.50 (0.43 to 0.57) <.001
Age‡ 1.00 (0.97 to 1.03)  .97
Sex: female vs male 0.91 (0.76 to 1.10)  .33
Rate of pharmacogenomic accrual§ 1.00 (0.96 to 1.05)  .95
Self-reported race by site
CALGB: nonwhite vs white 0.43 (0.39 to 0.48) <.001
CTSU: nonwhite vs white 0.51 (0.43 to 0.61) <.001
* Generalized estimating equation model accounts for variability of patient 
participation among the separate clinical trials by use of study as a “cluster 
variable,” because patients are clustered within individual trials. Reported P 
values are two-sided. CI = confidence interval; OR = odds ratio.
† Nonwhite = African American, Asian, other (Native American, Pacific Islander, 
mixed race); white = Caucasian; persons with unknown data for race were 
excluded from this analysis (n = 8252).
‡ Age was analyzed as a continuous variable, and OR is reported for 10-year 
increments.
§ Rate of pharmacogenomics accrual calculated as the number of patients 
accrued to the pharmacogenomics study at each institution per year, during 
the time the institution was actively accruing patients to the study and is 
presented in increments of 10.
Figure 1. Patient participation in pharmacogenomic (PGx) study by self-reported race. This histogram illustrates the percentage of patients participating in the phar-
macogenomic component of each clinical trial (identified by clinical trial study number and disease stie), stratified by self-reported race (white: Caucasian; and non 
white: African American, Asian, other (American Indian, Alaska Native, or mixed race). Open bars represent whites; shaded bars represent nonwhites.











etc., up to the highest diversity estimated [80%-89%]). Nearly 80% 
of institutions (507/652, 77.7%) were assigned an MPF-derived 
diversity score of less than 20%. High-diversity categories (50%-
89% diversity) were assigned to 24 different institutions and rep-
resented 226 patients. Two groups of high-diversity institutions 
are observed with different participation: one group includes 
high-diversity institutions (60%-79%) with high median par-
ticipation rates (84%-89%); the other group, (diversity categories 
50%-59% and 80%-89%) had lower median participation rates 
(66.7% and 12.5%, respectively).
Discussion
This study demonstrates that pharmacogenomic stud-
ies are clearly achievable in the context of publically funded 
multicenter cancer clinical trials, with over 80% of patients par-
ticipating across six different types of cancer. This indicates an 
important pathway to the myriad systematic pharmacogenomic 
discovery and replication studies needed to move the molecular 
age of cancer medicine forward (30). However, we also identified 
the need to optimize both patient and institution participation 
in these studies.
Institutional diversity (minority participation fraction) was 
used as a proxy for institutional racial diversity. This variable 
was calculated as part of an exploratory analysis to better 
understand the statistical interaction observed between self-
reported race (white vs nonwhite) and site (CALGB vs CTSU). 
Within both types of registration sites, nonwhite patients had 
a statistically significantly lower participation compared with 
white patients. In a multivariable analysis, the proxy diversity 
Table 4. Multivariable analysis stratified by race, including diversity*
All trials
White patients (n = 6542) Nonwhite patients (n = 1084)
OR (95% CI) P OR (95% CI) P
Site: CALGB vs CTSU 2.26 (1.68 to 3.04) <.001 1.79 (1.52 to 2.11) <.001
Age (10-year increase)† 0.96 (0.92 to 0.99) .05 1.03 (0.97 to 1.09) .31
Sex (female vs male) 0.94 (0.80 to 1.10) .44 0.86 (0.75 to 0.99) .03
Rate of pharmacogenomic accrual‡ 1.01 (0.92 to1.11) .83 1.04 (0.95 to 1.15) .41
Minority participation fraction (diversity 
variable)§ (10% increase)
0.94 (0.91 to 0.97) <.001 0.90 (0.81 to 1.00) .05
* Generalized estimating equation model accounts for variability of patient participation among the separate clinical trials by use of study as a “cluster variable,” 
because patients are clustered within individual trials. The odds ratios presented are from the model without the interaction terms. Reported P values are two-sided. 
CI = confidence interval; OR = odds ratio.
† Age was analyzed as a continuous variable, and OR is reported for 10-year increments.
‡ Rate of pharmacogenomics accrual calculated as number of patients accrued to the pharmacogenomics study at each institution per year, during the time the 
institution was actively accruing patients to the study and is presented in increments of 10.
§ The minority participation fraction (MPF) was used as a proxy for institutional racial diversity, analyzed as a continuous variable, and OR is reported for 10% 
increases. The MPF reflects the proportion of nonwhite patients registered by an institution to any CTSU cooperative group study (from RSS database for Cancer 
Trials Support Unit). The MPF diversity variable was only assigned to sites with more than 10 patients enrolled in the seven pharmacogenomic clinical trials.
Figure 2. Patient participation in pharmacogenomic study by site and trial. This histogram illustrates the percentage of patients participating in the pharmacogenomic 
(PGx) component of each clinical trial (identified by clinical trial study number and disease site), stratified by registration process (CALGB: patient was registered 
through a CALGB institution; CTSU: patient was registered through the Clinical Trials Support Unit [CTSU]).











variable (minority participation fraction) was an independent 
predictor of participation, showing no evidence of interaction 
with the other covariates. The observation that some institu-
tions with “high diversity” (high MPF) had decreased participa-
tion among whites as well as nonwhites suggests that patients 
at institutions that serve a larger minority population may be 
less likely to provide the opportunity to participate in optional 
pharmacogenomic studies compared with those institutions 
that serve a lower fraction of minority patients. It also highlights 
that factors at the institution level, in addition to those at the 
patient level, may be barriers to participation in optional bio-
specimen studies. These are important observations, worthy of 
further evaluation in future prospective studies.
Guth and colleagues observed that place of care has impor-
tant implications for use of a clinical genomic test in breast 
cancer patients. In their study, use of the Oncotype Dx test was 
evaluated among minority and economically disadvantaged 
breast cancer patients receiving care in inner city hospitals. 
Patients treated at municipal hospitals were statistically signifi-
cantly less likely to have the Oncotype Dx test ordered compared 
with patients at tertiary care hospitals (31). These observations 
further suggest that characteristics of the individual institu-
tion, in addition to the patient, need to be carefully considered 
to better understand and address the causal relationships with 
observed disparities in care. The report of a large and growing 
disparity in black vs white breast cancer mortality among the 
largest cities in the United States (32) further underscores the 
need to assess factors associated with “place as well as race” 
(31).
Our study uniquely demonstrates that, even among individ-
uals who have already agreed to participate in a clinical research 
trial, some are not participating in the genetic component of the 
trial. One of the most important factors for this issue may be 
whether or not the patient had the opportunity to participate, ie, 
was approached to participate in the pharmacogenomic study. 
As an observational study, we cannot determine if the patient 
was approached and declined to participate or if the patient was 
only asked to participate in the treatment part of the study, not 
the pharmacogenomic component. Some studies suggest that 
racial and ethnic minorities in the United States are as willing 
to participate in health research as non-Hispanic whites, if they 
are asked (9,11,33).
A complex interplay of multiple factors acting as incentives 
and barriers to clinical research participation exist at the patient, 
clinician, institution, and community levels (9,12,14,34,35). The 
Accrual to Clinical Trials (ACT) model offers one approach to 
integrate factors at each of these levels, including norms, beliefs, 
attitudes, awareness, and opportunity, to improving ethnic/racial 
minority cancer patient accrual to cancer clinical trials (34). It is 
likely that many of these same issues apply to participation in 
pharmacogenomic studies. However, issues unique to genetic or 
genomic studies may also exist (36–39). At the patient level this 
includes mistrust (stemming not only from an individual’s fear 
of harm while participating in the genetic study, but also from 
misgivings about the consequences and ultimate uses of infor-
mation gathered from these studies) (23,39) and misrepresenta-
tion or misapplication of the genetic data to “reinforce racism” 
(22). At the clinician and institutional levels, additional factors, 
including awareness, perceived value, familiarity with pharma-
cogenomic research, and limited time, are also highly influential 
(6,9). Studies from our group and others indicate a wide variabil-
ity of clinician knowledge, comfort with interpreting results and 
adoption of cancer genomic tests, especially pharmacogenomic 
tests (40–43). In addition, it is feasible that some institutions 
may have given the priority and resources to provide a robust 
correlative science infrastructure, while others were not able 
Figure 3. Estimate of institutional “diversity” and PGx participation*. This figure graphically illustrates the overall relationship between the proxy for institutional 
diversity (minority participation fraction [MPF]) and participation in the pharmacogenomics component. MPF calculations were based on the percentage of nonwhite 
cancer patients that an institution registered to any CTSU cooperative group trial (nonwhite cancer patients/total cancer patients [white + nonwhite] registered to a 
CTSU trial by that institution). This information was obtained from the National Cancer Institute Regulatory Support System (RSS) database. MPF derived institutional 
diversity was categorized into 10 levels (0%; 1%-9%; 10%-19%, etc., up to the highest diversity estimated (80%-89%). The total number of institutions associated with 
each MPF-derived diversity category is indicated in parentheses along the x-axis. Box plots illustrate mean (diamonds), median (line), and interquartile range (IQR) of 
participation for each category (bottom and top edges of the box indicate IQR betwen the 25th and 75th percentiles). The whiskers that extend from each box indicate 
the range of values that are outside IQR but are close enough not to be considered outliers (a distance of less than or equal to 1.5*IQR). Any points that are a distance 
of more than 1.5*IQR from the box are considered to be outliers and are indicated by open circles.











to support collection and shipment of samples. Resource-poor 
institutions may focus on getting patients access to the drug 
study and not prioritize the time and effort to include optional 
biospecimen studies. Time pressures, a team approach to cor-
relative science, resources for education, and the lack of direct 
benefit, for either the patient or the institution, are all practical 
challenges for clinicians and institutions who wish to offer their 
patients opportunities to participate in genomic research (9). The 
findings that CALGB institutions recruit statistically significantly 
more patients to participate compared with CTSU sites and that 
some institutions with “higher diversity” (some of which may be 
resource poor because of location or other financial constraints) 
recruit fewer patients to participate further suggest that the 
expertise, resources, infrastructure, and culture of an institution 
may provide an environment that is conducive to enrollment 
on pharmacogenomic and other correlative science elements 
of complex clinical trials. Sufficient incentives such as institu-
tional participation credit for companion studies may also be a 
factor, especially for resource-poor institutions or for institutions 
only registering a few patients to a trial. Indeed, during this time 
period, it is our understanding that CALGB institutions were eli-
gible for greater per-patient support of companion studies than 
non-CALGB sites that registered patients through the CTSU.
Our study had areas of limitation. First, we excluded from 
our analysis patients with no known race. However, this only 
reflects 2.5% of the eligible patients registered to the clinical 
drug studies. Second, the diversity variable (MPF) used best avail-
able data to estimate institutional diversity, but future studies 
could employ a more accurate measure of minorities served. In 
addition, because of the need for a quantifiable calculation, the 
diversity variable was only calculated for those institutions reg-
istering at least 10 patients to a study, thus reflecting only 80% 
of the institutions in our study. Nonetheless, these findings are 
suggestive of important site characteristics that need to be con-
sidered in future studies. Third, the influence of financial support 
for correlative science could have an influence on accrual to the 
pharmacogenomics component. Site-specific data was not avail-
able in the public domain but could be a variable analyzed in 
future assessments. Despite these limitations, our findings war-
rant further study.
Participation in cancer pharmacogenomics and correlative 
studies can be influenced by a number of factors (9,34,35,44,45). 
The main findings of our study highlight a shift in the approach 
to understanding disparity, still considering patient factors but 
also shifting attention to factors associated with place where 
care is received. Our study demonstrates that race alone does 
not explain participation. Factors at the institutional level also 
need to be considered, many of which could not be measured in 
our observational study. These are issues that lend themselves 
to quantitation, intervention, and improvement, elements that 
are amenable to a prospective study design. The field now needs 
to interrogate the process of clinical trial participation at a more 
granular level, to prospectively identify and address causal rela-
tionships for disparate correlative science participation, and to 
avoid the generation of a new class of therapeutically under-
privileged patients, for whom the “best” application of modern 
cancer care lacks evidence and guidance.
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